Levamisole as an Adjuvant to Short-Course Therapy in Newly Diagnosed Pulmonary Tuberculosis Patients

BACKGROUND: The estimated incidence and prevalence of tuberculosis in India are 2.1 and 2.6 million cases respectively. Immunotherapy may shorten tuberculosis treatments and improve the immunity of individuals as well. Hence we study the efficacy of levamisole (LVM) (immunomodulator) as an adjuvant...

Descripción completa

Detalles Bibliográficos
Autores principales: Shamkuwar, Chetna Ashok, Meshram, Sushant Hiraman, Mahakalkar, Sunil M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5385702/
https://www.ncbi.nlm.nih.gov/pubmed/28516071
http://dx.doi.org/10.4103/2277-9175.203162

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5385702/
https://www.ncbi.nlm.nih.gov/pubmed/28516071
http://dx.doi.org/10.4103/2277-9175.203162

Ejemplares similares